Vosaroxin - Sunesis Pharmaceuticals

Drug Profile

Vosaroxin - Sunesis Pharmaceuticals

Alternative Names: AG-7352; AG-7352 hydrochloride; QINPREZO; SNS-595; SPC-595; Voreloxin

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Sunesis Pharmaceuticals; University of Texas M. D. Anderson Cancer Center; Vanderbilt-Ingram Cancer Center; Washington University School of Medicine; Weill Cornell Medical College
  • Class Antineoplastics; Carboxylic acids; Naphthyridines; Pyrrolidines; Quinolones; Small molecules; Thiazoles
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute myeloid leukaemia; Ovarian cancer

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase I/II Myelodysplastic syndromes
  • Preclinical Glioblastoma
  • Discontinued Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer

Most Recent Events

  • 07 Feb 2018 Sunesis Pharmaceuticals and Weill Cornell Medical College completes phase I/II trials in Myelodysplastic syndromes in USA (NCT01980056)
  • 16 Nov 2017 University of Ulm and Sunesis Pharmaceuticals plan a phase II trial for Acute myeloid leukaemia and Myelodysplastic syndromes (Combination therapy, In adults, In the elderly, Newly diagnosed) in Germany in December 2017 (NCT03338348)
  • 22 Aug 2017 Indiana University School of Medicine terminates a clinical trial in Acute myeloid leukaemia (In the elderly, First-line therapy, Combination therapy) in USA due to safety concerns (NCT02485353)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top